TransCelerate BioPharma Pushes for Clinical Trial Efficiency at SCOPE 2026
Event summary
- TransCelerate BioPharma will present seven sessions at SCOPE Summit 2026, focusing on clinical trial efficiency and patient-centered design.
- The conference takes place February 2-5, 2026, in Orlando, Florida.
- Topics include data collection optimization, protocol digitization, and pragmatic trial design.
- Representatives from Amgen, Merck, and Pfizer will participate in the sessions.
- TransCelerate aims to reduce trial complexity and improve patient outcomes through collaborative approaches.
The big picture
TransCelerate BioPharma's focus on clinical trial efficiency comes at a time when the industry faces increasing complexity and demand for faster, more patient-relevant trials. The organization's collaborative approach aims to address these challenges by leveraging digital transformation and pragmatic trial designs. With 18 member companies, TransCelerate is positioned to drive industry-wide changes in clinical research practices.
What we're watching
- Digital Transformation
- The pace at which digital protocols and automation will be adopted across clinical trials.
- Regulatory Alignment
- How collaboration between life science companies, regulators, and providers will impact trial design and execution.
- Patient Burden Reduction
- Whether efforts to optimize protocol data collection will significantly reduce site and patient participation burden.
Related topics